GlobeNewswire

SmartWay Logistics is Live with 3Gtms Transportation Management System

Dela

Robust functionality, ability to self-configure and partnership approach drive big efficiency gains for Dutch fourth party brand

 

SHELTON, Conn., July 25, 2018 (GLOBE NEWSWIRE) -- 3Gtms, Inc., a global provider of Tier 1 transportation management software, announced that SmartWay Logistics is now live with its 3G-TM transportation management system (TMS). Headquartered in the Netherlands, SmartWay Logistics is the 4PL brand of Van der Wal, a logistics service provider with locations throughout Europe, delivering trucking, 3PL and 4PL services. SmartWay Logistics chose 3Gtms because of its powerful functionality, the ability to self-configure the TMS, and the expert reputation of the 3Gtms team.

SmartWay Logistics sought to streamline its operations by maximizing the automation of its order entering and handling. With increased automation enabled by 3Gtms, SmartWay Logistics employees have refocused their time and efforts on larger business objectives and on ensuring stellar customer service. From planning and optimization through rate management, integration, execution and payment, the company has expanded visibility into its shipments, as well as access to intuitive customer portals that improve the speed and accuracy of routing requests and order management.

Furthermore, SmartWay Logistics is leveraging the optimization power of 3Gtms to optimize in real-time and to build loads that can actually be executed, all resulting in significant cost and time savings for the company and her clients.

"Since implementing 3Gtms, we've greatly simplified the way we enter and process orders, and we have seen big gains in efficiency and cost savings by leveraging 3Gtms' powerful optimization engine," said Edwin Schouten, 4PL business unit manager. "We also value our ability to self-configure the TMS, as we need to adjust quickly to meet our customers' needs. The 3Gtms team truly understands our business and they are enthusiastic about helping us solve problems. They are a terrific partner."

"SmartWay Logistics understands the value of automation and efficiency, and their superior customer service is a result of that commitment," said Mitch Weseley, CEO at 3Gtms. "We're honored to work so closely with their team to improve their productivity and to leverage 3G-TM to address their most pressing customer challenges."

About 3Gtms
3Gtms is the fastest growing Tier 1 transportation management system (TMS) provider and is committed to giving mid-to-large shippers and logistics service providers a competitive advantage through technology. Whether you move $5 million or $5 billion in freight, the 3G-TM solution seamlessly manages the full transportation lifecycle, including transportation planning and optimization, execution and settlement, empowering customers to make better shipping decisions while meeting their service goals. 3Gtms' reputation for being a trusted partner is reflected in customer satisfaction and retention rates that are unmatched in the TMS industry. For more information, visit: www.3gtms.com.

About SmartWay Logistics
SmartWay Logistics is committed to make a serious contribution to a sustainable transport sector. Not only because it is necessary for the environment, but mainly because it produces profit. And also because it is possible: SmartWay Logistics has the knowledge, experience and technology at its disposal with which it can kick start the transition to sustainable transport. Based on continuous data analysis, SmartWay Logistics devises out of the box solutions to structurally improve transport efficiency in a smart way. This is how SmartWay Logistics pursues her audacious goal: to limit empty running to an absolute minimum.

About Van der Wal
Van der Wal was founded in 1924 by Toon van der Wal as a taxi company. The current owner, Henk van der Wal, took over the reins in 1985. The company has managed to develop into an all-round logistics service provider during the course of the past 90 years, with sites in the Netherlands, the UK, Poland, Rumania, Azerbaijan, Kazakhstan and Russia. Van der Wal has also been offering 3PL and 4PL activities for the last 10 years, in addition to the purely physical transport facilities. Van der Wal employs approximately 350 employees. For more information, visit http://www.vanderwal.company

Media Contact
Chuck Fuerst
3Gtms, Inc.
203.567.4610, x443
cfuerst@3gtms.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: 3Gtms via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum